Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia

NCT00047190 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

NIH

Sponsor class

Conditions

Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis

Interventions

DRUG: tipifarnib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)